)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Chimerix
Chimerix (CMRX) investor relations material
Chimerix has been delisted
Chimerix Q4 2024 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2024 earnings summary21 Mar, 2025
Executive summary
FDA accepted NDA for dordaviprone to treat recurrent H3 K27M-mutant diffuse glioma; PDUFA action date set for August 18, 2025.
Jazz Pharmaceuticals to acquire Chimerix for $8.55 per share in cash, totaling ~$935 million; expected to close in Q2 2025.
Chimerix continues to advance dordaviprone and ONC206 clinical programs.
Financial highlights
Q4 2024 net loss was $23.0 million ($0.25/share) vs. $18.2 million ($0.20/share) in Q4 2023.
Full-year 2024 net loss was $88.4 million ($0.99/share) vs. $82.1 million ($0.93/share) in 2023.
Q4 2024 R&D expenses rose to $17.7 million from $15.6 million year-over-year; G&A expenses increased to $7.0 million from $5.2 million.
Full-year 2024 R&D expenses were $74.6 million, up from $68.8 million; G&A expenses decreased to $22.2 million from $24.6 million.
Cash and investments totaled $140.1 million at year-end 2024; no outstanding debt.
Outlook and guidance
Preparing for potential commercial launch of dordaviprone, pending FDA approval.
Anticipates closing of Jazz acquisition in Q2 2025, subject to customary conditions.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Chimerix
- Dordaviprone NDA submission targets accelerated approval for H3K27M-mutant glioma by Q3 2025.CMRX
FDA Announcement - Q3 net loss narrowed to $22.9M as dordaviprone and ONC206 clinical programs advanced.CMRXQ3 2024
- Dordaviprone advances to phase III with strong data; ONC206 and TEMBEXA add pipeline and financial strength.CMRXH.C. Wainwright 26th Annual Global Investment Conference 2024
- Q2 net loss was $20.7M as late-stage oncology trials advanced and cash runway remains strong.CMRXQ2 2024
- Phase III glioma trial nears key survival data; ONC206 and Australia approval advance in 2024.CMRXJefferies 2024 Global Healthcare Conference
Chimerix
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Chimerix Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for life-threatening diseases, including viral infections and cancer. The company's portfolio includes antiviral treatments and oncology therapies aimed at addressing unmet medical needs. Chimerix works on developing novel drug candidates to improve outcomes for patients with limited treatment options, particularly in areas such as immunotherapy and targeted therapies. The company is headquartered in Durham, North Carolina, and its shares are listed on the NASDAQ.